

Edgar Filing: NOVADEL PHARMA INC - Form 8-A12B

NOVADEL PHARMA INC  
Form 8-A12B  
May 10, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
-----

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(B) OR 12(G) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Novadel Pharma Inc.

-----  
(Exact Name of Registrant as Specified in its Charter)

Delaware

22-2407152

-----  
(State of Incorporation or Organization) (I.R.S. Employer Identification No.)

25 Minneakoning Road, Flemington NJ

08822

-----  
(Address of Principal Executive Offices)

(Zip Code)

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

Securities Act registration statement file number to which this form relates:  
N/A

Securities to be registered pursuant to Section 12(b) of the Act:

Title of Each Class  
To be so Registered

Name of Each Exchange on Which  
Each Class is to be Registered

Common Stock, \$.001 par value

American Stock Exchange LLC

-----  
Securities to be registered pursuant to Section 12(g) of the Act: None

1

ITEM 1. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED.

A description of the registrant's common stock can be found on page 32 of the registrant's Registration Statement on Form SB-2/A, Registration No. 333-112852 (under the Caption "Description of Securities - Common Stock"), filed with the Securities and Exchange Commission on March 25, 2004, and incorporated herein by reference.

ITEM 2. EXHIBITS.

Edgar Filing: NOVADEL PHARMA INC - Form 8-A12B

N/A

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: May 10, 2004

NOVADEL PHARMA INC.

By: /s/ Gary A. Shangold, M.D.

-----  
Gary A. Shangold, M.D.  
President and Chief Executive Officer